FDA Brief

Warning letters Biologics

FDA warning letter to

Genzyme Ireland Limited

High riskIssued Jun 22Posted Jun 30Center for Biologics Evaluation and Research (CBER)

Genzyme Ireland's Waterford biologics plant cited for quality unit and data integrity failures across two licensed products.

What happened

FDA inspected the Genzyme Ireland facility in Waterford, Ireland from January 12 to January 20, 2026, and issued a Form FDA-483 listing inspectional observations at the close. Investigators found incomplete laboratory records, environmental monitoring records that could not be traced back to the instruments that generated them, testing repeated up to 11 times without documentation, and deviations cancelled without investigation. FDA reviewed the company's responses of February 10, February 26, and April 8, 2026 and found they did not address the underlying failure of the quality unit.

What FDA found

  1. The quality unit did not make sure the products were made according to CGMP and met their specifications.

    21 CFR 211.22
  2. Laboratory records were incomplete: repeated particulate excursions and test failures were left out of records, and one test was repeated up to 11 times without documentation.

    21 CFR 211.194(a)
  3. Environmental monitoring records could not be traced to the specific air samplers, and logbooks did not match when staff actually entered and left the cleanrooms.

    21 CFR 211.194(a)
  4. Staff used uncontrolled review checklists that were later thrown away, and changes to records could not always be traced to a person.

    21 CFR 211.194(a)
  5. The firm cancelled many deviations without investigating the root cause or assessing the effect on the product.

    21 CFR 211.192
  6. The investigation of Deviation QE-1679805 into orange material found in filling had inconsistencies, and its conclusion that there was no product impact was not adequately supported.

    21 CFR 211.192

What FDA wants

FDA tells the company to explain how its quality unit failed to detect and prevent these violations and to describe systemic corrective actions, including a full assessment of the scope of data integrity problems, an expanded retrospective review of all cancelled deviations, and a revised investigation of Deviation QE-1679805. The written response is due within 15 working days of receiving the letter.

Who should pay attention

  • hospitals and transplant centers that use Thymoglobulin
  • clinicians and patients using Altuviiio for bleeding disorders
  • quality units at sterile biologics manufacturers that rely on similar deviation and lab record practices

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk